000			03350na a2200229 4500
003			PC8594
005			20180417114644.0
008			130622s2013
040			_cH12O
041			_aeng
100			_9501 _aHawkins Carranza, Federico Gustavo _eEndocrinología y Nutrición
100			_aMartínez Díaz-Guerra, Guillermo _9760 _eEndocrinología y Nutrición
245	0	0	_aEarly changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis _h[artículo]
260			_c2013. _bOsteoporosis International,
300			_a24(12):2971-2981.
500			_aFormato Vancouver: Farahmand P, Marin F, Hawkins F, Möricke R, Ringe JD, Glüer CC, et al. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos Int. 2013;24(12):2971-81.
504			_aContiene 57 referencias, 2 figuras y 2 tablas.
520			_aResumen: Changes of the bone formation marker PINP correlated positively with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis (GIO) who received 18-month treatment with teriparatide, but not with risedronate. These results support the use of PINP as a surrogate marker of bone strength in GIO patients treated with teriparatide. Introduction To investigate the correlations between biochemical markers of bone turnover and vertebral strength estimated by finite element analysis (FEA) in men with GIO. Methods A total of 92 men with GIO were included in an 18-month, randomized, open-label trial of teriparatide (20 mu g/day, n=45) and risedronate (35 mg/week, n=47). High-resolution quantitative computed tomography images of the 12th thoracic vertebra obtained at baseline, 6 and 18 months were converted into digital nonlinear FE models and subjected to anterior bending, axial compression and torsion. Stiffness and strength were computed for each model and loading mode. Serum biochemical markers of bone formation (amino-terminal-propeptide of type I collagen [PINP]) and bone resorption (type I collagen cross-linked C-telopeptide degradation fragments [CTx]) were measured at baseline, 3 months, 6 months and 18 months. A mixed-model of repeated measures analysed changes from baseline and between-group differences. Spearman correlations assessed the relationship between changes from baseline of bone markers with FEA variables. Results PINP and CTx levels increased in the teriparatide group and decreased in the risedronate group. FEA-derived parameters increased in both groups, but were significantly higher at 18 months in the teriparatide group. Significant positive correlations were found between changes from baseline of PINP at 3, 6 and 18 months with changes in FE strength in the teriparatide-treated group, but not in the risedronate group. Conclusions Positive correlations between changes in a biochemical marker of bone formation and improvement of biomechanical properties support the use of PINP as a surrogate marker of bone strength in teriparatide-treated GIO patients.
710			_9292 _aServicio de Endocrinología y Nutrición
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc8594.pdf _ySolicitar documento
942			_2ddc _cART _n0
999			_c8594 _d8594